Biochemical and Biophysical Research Communications
KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts
Section snippets
Materials and methods
Materials and reagents. The reagents used in the present study were obtained as follows: Eagle’s minimum essential medium-α (MEM-α) was obtained from Nikken BioMed., Kyoto, Japan; paraformaldehyde, Triton X-100 and Hoechst 33342 were from Sigma–Aldrich, St. Louis, MO, USA; the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was from Promega, Madison, WI, USA; the Cell
KL-6 accelerates proliferation of human lung fibroblasts
The presence of 100 U/ml of KL-6 in the culture medium was found to accelerate cell proliferation in all of seven human lung fibroblasts examined (Table 1). CCD-11Lu fibroblasts were selected for further experiments based on the strength of their response to KL-6. As shown in Fig. 1A, the presence of KL-6 from 1 to 1000 U/ml accelerated the proliferation of CCD-11Lu in a dose-dependent manner. Furthermore, addition of anti-KL-6 mAb inhibited the KL-6-induced proliferation of CCD-11Lu in a
Discussion
In the present study, we have demonstrated that KL-6 molecules have a pro-proliferative effect on all human lung fibroblasts that were examined in vitro. We also demonstrated that KL-6 has an anti-apoptotic effect in that it rescues lung fibroblasts from apoptosis induced by anti-Fas mAb and cycloheximide. In addition, we confirmed that addition of anti-KL-6 mAb to the cell culture blunted both the pro-proliferative and anti-apoptotic effects of KL-6 on CCD-11Lu cells in a dose-dependent
References (35)
- et al.
Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia
Respir. Med.
(1997) - et al.
Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer
Chest
(1992) - et al.
Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis
Chest
(2003) - et al.
Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth inhibition
J. Biol. Chem.
(1996) - et al.
Fibroblast growth factor-2 induction of platelet-derived growth factor-C chain transcription in vascular smooth muscle cells is ERK-dependent but not JNK-dependent and mediated by Egr-1
J. Biol. Chem.
(2004) - et al.
Casper/c-FLIP is physically and functionally associated with NF-kappaB1 p105
Biochem. Biophys. Res. Commun.
(2003) - et al.
Insulin potentiates EGFR activation and signaling in fibroblasts
Biochem. Biophys. Res. Commun.
(2004) - et al.
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification
Am. J. Respir. Crit. Care Med.
(1998) - et al.
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy
Ann. Intern. Med.
(2001) - et al.
Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma
Jpn. J. Clin. Oncol.
(1988)
Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9
Int. J. Cancer Suppl.
New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6
Chest
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases
Am. J. Respir. Crit. Care Med.
KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease
Am. Rev. Respir. Dis.
Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis
Am. J. Respir. Crit. Care Med.
Circulating KL-6 levels in patients with drug induced pneumonitis
Thorax
Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis
Am. J. Respir. Crit. Care Med.
Cited by (87)
Systemic sclerosis and interstitial lung disease: From pathogenesis, to screening, diagnosis, and classification
2024, Revista Colombiana de ReumatologiaPrognostic value of serum Krebs von den Lungen-6 (KL-6) levels in COVID-19 pneumonia
2023, Respiratory Medicine and ResearchYKL-40 and KL-6 Levels in Serum and Sputum of Patients Diagnosed With Hypersensitivity Pneumonitis
2022, Journal of Allergy and Clinical Immunology: In PracticeAutoimmunity in interstitial lung disease
2022, Translational Autoimmunity: Autoimmune Disease Associated with Different Clinical FeaturesHeme Oxygenase-1 in Patients With Interstitial Lung Disease: A Review of the Clinical Evidence
2021, American Journal of the Medical Sciences